Oncology Genetics

The clinical utiliy of cancer genomics in patient diagnosis and management is multifaceted; genetics are used to:

• Assist with patient diagnosis, such as in myeloproliferative neoplasms (MPNs) and the detection of JAK2 V617F, JAK2 Exon 12, MPL515 and CALR mutations
• Determine patient prognosis, such as in acute myelogeneous leukemia (AML) and the detection of mutations in CEBPA, NPM1, and FLT3
• Qualify patients for therapies that target specific genomic alterations, such as EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC or HER2 targeted therapies in HER2 positive breast cancer
• Determine patient prognosis, such as in acute myelogeneous leukemia (AML) and the detection of mutations in CEBPA, NPM1, and FLT3

To be able to meet the needs of these genomic advancements, new technologies are being employed, such as tumor sequencing by next generation sequencing (NGS). Through the Northwell Health Genomics Alliance, a large menu of oncology genetic testing is available including NGS, FISH, PCR, and array CGH. Common oncology genetic tests are listed below.

Commonly Ordered Tests

• B821 OnkoSight Solid Tumor Panel
• B823 OnkoSight Myeloid Disorder Panell
• H125 OnkoSight Lung Cancer Panel + ALK and ROS1 by FISH
• B822 OnkoSight Colorectal Cancer Panel
• B893 OnkoSight MDS Panell

See All Tests for Oncology Genetics